Antibody Drug Conjugate Market is estimated to be US$ 27.0 billion by 2030 with a CAGR of 23.5% during the forecast period

 



Antibody drug conjugate market accounted for US$ 3.3 billion in 2020 and is estimated to be US$ 27.0 billion by 2030 and is anticipated to register a CAGR of 23.5%. Antibody-drug conjugates or ADCs are biopharmaceutical drugs designed for targeted therapy for treating various type of cancer. ADCs are expose to target and kill tumor cells while sparing healthy cells. As of now 59npharmaceutical companies developed ADCs. These are complex molecules composed of antibody and have capability to target cancer cells by discriminating healthy tissues and diseased tissues.

The report " Global Antibody Drug Conjugate Market, By Technology (Cleavable Linker and Non-Cleavable Linker), By Application (Blood Cancer, Ovarian Cancer, Lung Cancer and Brain Tumor), By Distribution Channel (Hospital Pharmacies, Online Pharmacies and Others) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030”

Key Highlights:

  • In June 2019, Seattle Genetics and Astellas Pharma, Inc. announced first cohort of pivotal phase 2 clinical trial called EV-201 which is antibody-drug conjugate rapidly shrunk tumor in most patients.
  • In March 2019, LegoChem Bioscience and Takeda collaborated and got license to develop an antibody-drug conjugate which is used for immune-oncology.

Analyst View:

Increasing incidence of cancers is the major growth driver of global Antibody Drug Conjugate market. Many key players are coming with new drugs and new technologies like there were only two drugs to treat the cancer but now 40 molecules are in clinical trials. Various organizations such as W.H.O., FEAT, and others along with the government are spreading awareness about this syndrome condition which is anticipated to facilitate market growth in the forecast period.

Before purchasing this report, request a sample or make an inquiry by clicking the following link:

https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/2230

 

Key Market Insights from the report:

The global antibody drug conjugate market accounted for US$ 3.3 billion in 2020 and is estimated to be US$ 27.0 billion by 2030 and is anticipated to register a CAGR of 23.5%. The Global Antibody Drug Conjugate Market is segmented based on the technology, application, distribution channel and region.

  • On the basis of Technology, the global antibody drug conjugate market is segmented into cleavable linker and non-cleavable linker.
  • Based on application, the target market is segmented into Blood Cancer, Ovarian Cancer, Lung Cancer and Brain Tumor.
  • On the basis of distribution channel, the target market is segmented into hospital pharmacies, online pharmacies and others.
  • By region, the Global Antibody Drug Conjugate Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Europe is the worldwide leader in the antibody drug conjugate in terms of revenue, due to the developed healthcare system and health awareness among people.

Competitive Landscape:

The key players operating in the global antibody drug conjugate market includes F. Hoffmann-La Roche Ltd; Seattle Genetics, Inc.; Pfizer Inc.; Takeda Pharmaceutical Company Limited; AbbVie Inc.; Immunomedics; and ImmunoGen Inc.

The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.

About Prophecy Market Insights

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

To know more

Contact Us:

Sales

Prophecy Market Insights

  1 860 531 2701

Email- sales@prophecymarketinsights.com

 

Comments

Popular posts from this blog

Inulin Market is estimated to be US$ 2.29 billion by 2030 with a CAGR of 5.5% during the forecast period

Intraocular Lens Market is estimated to be US$ 7.9 billion by 2032 with a CAGR of 7.2% over the forecast period (2022-2032)